Latest Pharmaceuticals news and updates from Switzerland. AI-curated articles covering Pharmaceuticals topics.
Swiss pharmaceutical giant Novartis has announced the acquisition of British start-up Myricx Bio for an initial $1.1 billion, a strategic move to bolster its portfolio of antibody-drug conjugates for treating various solid tumours.
A look at major developments in Switzerland's corporate world. The SNB confirms UBS's crisis resilience as the bank plans a US expansion, Roche announces a successful trial for a new lung cancer drug, and retailer Migros opens its first 24-hour automated supermarket.
Severin Schwan, Chairman of Swiss pharmaceutical giant Roche, has heavily criticized the protectionist policies of the United States and China at the Swiss Economic Forum, stating they are disrupting the company's structures and comparing US tariff strategies to 'blackmail'.
Swiss generics giant Sandoz is escalating a trade dispute, preparing a complaint to the European Commission against what it calls heavily subsidised, low-priced penicillin imports from China that distort competition and create strategic health vulnerabilities.
As part of a broader M&A spending spree, Swiss pharmaceutical giant Novartis is set to acquire US biotech firm Avidity Biosciences for approximately $12 billion. The deal is aimed at strengthening Novartis's neuroscience business and is one of the largest transactions in a record-breaking year for Swiss M&A.
Switzerland's industrial sector saw production fall sharply by 7.1% in the first quarter of 2026 compared to the previous year. The decline was driven by a substantial 20.4% contraction in the crucial pharmaceutical industry, signaling economic headwinds for the country.
Switzerland's drug regulator, Swissmedic, is closely monitoring the drug Tavneos after its Japanese distributor warned doctors against new prescriptions following 20 deaths since 2021. US and European agencies are also reviewing the drug's approval amid safety concerns.
According to a new EY study, Switzerland's largest companies invested heavily in innovation in 2025, achieving the world's third-highest research intensity rate, driven primarily by the pharmaceutical sector.
Swiss pharmaceutical giant Roche has announced an agreement to acquire PathAI, a US-based artificial intelligence specialist, for $750 million. The acquisition aims to bolster Roche's position in AI-driven diagnostics and accelerate the development of personalized medicine.
Swiss pharmaceutical giant Novartis is strengthening its US manufacturing footprint with a new facility in North Carolina. The plant will produce active ingredients for both solid medications and advanced RNA-based therapies as part of a multi-billion dollar investment plan.
Swiss pharmaceutical giant Novartis has reported a decline in Q1 turnover, attributing the pressure to the loss of patent protection on billion-euro drugs like Entresto. The company is bracing for a significant impact from copycat drugs throughout the year.
Swiss pharmaceutical firm Roche announced first-quarter sales of CHF 14.7 billion, a 5% decrease in its reporting currency due to the strong franc. However, the company highlighted a 6% increase at constant exchange rates, driven by its Pharmaceuticals Division, which met analyst targets.
The conflict disrupting the Strait of Hormuz has renewed concerns over Switzerland's fragile pharmaceutical supply chains, a vulnerability exposed during the Covid-19 pandemic. The Federal Office for National Economic Supply confirms that essential medicines remain the primary category at risk of shortages.
Vasant Narasimhan, CEO of Swiss pharma giant Novartis, has been appointed to the board of AI company Anthropic. The move signals a strategic deepening of the ties between the pharmaceutical industry and the world of artificial intelligence, with major implications for future drug development.
The US administration has confirmed a new 15% tariff on Swiss pharmaceutical exports, part of a broader strategy to bolster domestic production. This move directly impacts a cornerstone of the Swiss economy and follows earlier reports anticipating duties of up to 100%.
US policies aimed at lowering prescription drug prices are forcing Swiss pharmaceutical companies like Novartis and Roche to reassess their European strategies. Companies are signing 'Most Favoured Nation' deals to align prices, which could reshape investment and innovation in Switzerland's vital pharma sector.
The Basel-based pharmaceutical supplier Lonza is selling its capsules and health ingredients business to British private equity firm Lone Star Funds in a deal expected to complete in the second half of 2026.
Swiss medicines regulator Swissmedic has approved Kisunla (donanemab) for early-stage Alzheimer's but not Leqembi (lecanemab), a drug already available in over 50 countries. The decision leaves Swiss patients with fewer advanced treatment options compared to many other nations.
Swiss pharmaceutical group Galenica has announced it will cease production at its Bichsel subsidiary by the end of the year, citing a lack of competitiveness. The move places up to 170 jobs at risk by the end of 2026.
Swiss pharmaceutical group Galenica has announced it will stop pharmaceutical production at its Bichsel subsidiary by the end of the year due to a lack of competitiveness. The move is expected to result in the loss of up to 170 jobs by the end of 2026.
From trusted Swiss news outlets